Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) and keeping the price target at $95.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ed Arce’s rating is based on several promising developments within Ultragenyx Pharmaceuticals. The company has announced a significant milestone in their ongoing Phase 3 Orbit study, which is focused on setrusumab, a monoclonal antibody aimed at reducing fracture risk in patients with osteogenesis imperfecta. The recent data shows a notable reduction in fracture incidence and meaningful improvements in bone mineral density, suggesting the treatment’s effectiveness. These results are expected to support a Biologics License Application filing, marking a crucial step forward for the company.
Additionally, Ultragenyx is making progress with its GTX-102 program for Angelman syndrome. The company aims to complete enrollment for the Phase 3 Aspire study by the second half of 2025, which targets cognitive improvements in affected children. The study’s design and anticipated outcomes, along with the initiation of a new Phase 2/3 Aurora study, reflect a robust pipeline that positions Ultragenyx for future growth. These advancements contribute to Ed Arce’s Buy rating, indicating confidence in the company’s long-term potential.
According to TipRanks, Arce is a 5-star analyst with an average return of 18.6% and a 48.50% success rate. Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Akero Therapeutics, and Acurx Pharmaceuticals.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $86.00 price target.